Work

698 - Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis

Year: 2024

Type: article

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae266.072

Authors: Andrew Blauvelt, Raj Chovatiya, Joseph F Merola, Stephan Weidinger, Ken Igawa, Efstathios Zikos, Christine Weber, Jennifer Wang, Cori Gray

Institutions: Rosalind Franklin University of Medicine and Science, The University of Texas Southwestern Medical Center, University Hospital Schleswig-Holstein, Dokkyo Medical University, Sanofi (Belgium), Sanofi (France)

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401435951

FWCI: 0.342

Cites:

Cited by: 1

Related to: 10